Nhau dzekambani
Kushanda Kwenguva Yakareba kweCD19 CAR T-Cell Therapy muKurapa Yakadzokazve / Refractory Acute Lymphoblastic Leukemia
Chidzidzo chepasi chinoratidza kubudirira kwenguva refu kweCD19 CAR T-cell therapy mukurapa varwere vane relapsed/refractory acute lymphoblastic leukemia (ALL) zvichitevera allogeneic hematopoietic stem cell transplantation, ichipa tariro itsva muhematology.
Bioocus Inosimudzira Muganho muKurapa Pediatric Acute Lymphoblastic Leukemia
Bioocus iri pamberi mukugadzira chizvarwa chinotevera cheCAR-T marapirwo. Chinyorwa chazvino chakaitwa naDr. Chunrong Tong nechikwata chake pachipatara cheLu Daopei chinoratidza kufambira mberi kwakanyanya uye matambudziko mukushandiswa kwechizvarwa chechipiri cheCD19 CAR-T kurapwa muvarwere vevana, zvichiratidza kuzvipira kwaBiocus pakurapa kenza.
Kupayona CAR-T Therapy muB-cell Acute Lymphoblastic Leukemia Inoratidza Kubudirira Kusati Kwamboitika
Chidzidzo chepasi chinosimbisa kushanda kunoshamisa kweCAR-T cell therapy mukurapa B-cell Acute Lymphoblastic Leukemia (B-ALL). Tsvagiridzo iyi, inosanganisira kubatana neBIOOCUS neLu Daopei Hospital, inoratidza kufambira mberi kwakakosha, kutanga kurapwa senzira yakakosha yekurapa.
Innovative CAR-T Cell Therapies Shandura Kurapa kweB Cell Malignancies
Vatsvagiri vanobva kuLu Daopei Hospital uye vanobatana nedzimwe nyika vanoongorora nzira dzekurapa dzeCAR-T cell, zvichipa tariro kune varwere vane B cell malignancies. Ichi chidzidzo chinosimbisa kufambira mberi mukugadzira nekushandisa, kuratidza mhedzisiro inovimbisa uye mukana wezvitsva zveramangwana.
Kuwedzera Antitumor Kubudirira kwe4-1BB-Yakavakirwa CD19 CAR-T Masero muKurapa B-ALL
Zvichangoburwa zvidzidzo zvekiriniki zvinoratidza kuti 4-1BB-based CD19 CAR-T masero anoratidza hukuru hweantitumor efficacy kana ichienzaniswa neCD28-based CAR-T masero mukurapa kudzokazve kana refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
Chipatara cheLu Daopei's Low-Dose CD19 CAR-T Therapy Inoratidza Mibairo Inovimbisa muB-ALL Varwere
Ongororo ichangoburwa pachipatara cheLu Daopei yakaratidza kushanda kwepamusoro uye kuchengetedzeka kweyepasi-dose CD19 CAR-T cell therapy mukurapa refractory kana kudzokazve B acute lymphoblastic leukemia (B-ALL) varwere. Tsvakurudzo, iyo yaisanganisira varwere ve51, yakaratidza chiyero chinoshamisa chekuregererwa nemigumisiro shoma.
Novel Promoter Strategy Inovandudza Kuchengetedzeka uye Kushanda kweCAR-T Therapy muAcute B Cell Leukemia.
Chipatara cheLu Daopei neHebei Senlang Biotechnology vazivisa zvinovimbisa zvakawanikwa kubva muongororo yavo yazvino pamusoro pekuchengetedza uye kushanda kweCAR-T kurapwa kweacute B cell leukemia. Kudyidzana uku kunotaridza kugona kwenovel CAR-T masero magadzirirwo ekusimudzira mhedzisiro yemurwere.
Kubudirira Kudzidza Kunoratidza Kuchengetedzeka uye Kushanda KweCAR-T Therapy muKurapa B-Cell Malignancies.
Chidzidzo chitsva chinotungamirwa naDr. Zhi-tao Ying kubva kuPeking University Cancer Hospital yakaratidza kuchengetedzwa uye kushanda kweIM19 CAR-T cell therapy mukurapa kudzokazve uye kudzoreredza B-cell hematologic malignancies. Rakadhindwa muChinese Journal of New Drugs, chidzidzo chinoshuma kuti 11 kubva kuvarwere ve12 vakawana kuregererwa kwakakwana pasina migumisiro yakaipisisa, kuratidza kukwanisa kweIM19 sechivimbiso chekurapa kusarudzwa kune varwere vane dzimwe nzira dzisina kukwana.
Gore negore Clinical Blood Management uye Transfusion Technology Training Yakaitwa paYanda Ludaopei Hospital
Iyo 2024 Yepagore Kudzidziswa kweClinical Ropa Management uye Transfusion Tekinoroji muSanhe City yakaitwa zvakabudirira paYanda Ludaopei Hospital. Chiitiko ichi chine chinangwa chekusimudzira manejimendi eropa rekiriniki uye kuchengetedzwa kwekuwedzerwa ropa kuburikidza nemisangano yakazara yekudzidziswa inopindwa nevanopfuura zana vezvehutano vehutano kubva kumasangano akasiyana ekurapa.
Kukurudzira Hutano uye Kupora: Kuchengeta Kwezuva Nezuva Kwevarwere veLeukemia
Kuve nechokwadi chekuchengetedza uye kugadzika chiitiko chekurapa kwevarwere veleukemia kunosanganisira kungwarira kwezuva nezuva, kusanganisira hutsanana kwezvakatipoteredza, hutsanana hwemunhu, chikafu, uye kurovedza muviri kwakakodzera. Gwaro iri rinopa matipi akakosha ekutarisira kwakanaka kwezuva nezuva kutsigira kupora.
NS7CAR-T Cell Therapy Inoratidza Vimbiso Yekurapa R/R T-ALL/LBL
Ongororo ichangoburwa inoratidza kushanda nekuchengetedzeka kweNS7CAR-T cell therapy mukurapa kudzokororwa kana refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) uye T-cell lymphoblastic lymphoma (R/R T-LBL). Kurapa uku kunopa tariro itsva kune varwere vane hutsinye mhando dzegomarara idzi.
Kuzivisa iyo 2024 Yegore Lu Daopei Hematology Forum muna Nyamavhuvhu
Musangano wechigumi nembiri weLu Daopei Hematology Forum wakarongwa kuti uitwe muna Nyamavhuvhu 23-24, 2024, paBeijing International Convention Center. Joinha isu panhaurirano dzine hungwaru uye kufambira mberi kwazvino muhematology.